Kincell Bio engineers cells into therapies and manufactures commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programmes. Kincell provides analytical development, CMC consulting and early-stage GMP manufacturing focusing on immune cell therapies.

Kineticos Ventures has investments including biotechs and life science services who want to transform drug development. The company funds research into oncology, neurosciences and rare diseases.

Kincell now has a facility at its Gainesville site, with an ambition to grow bigger.

Shailesh Maingi, founder of Kineticos Ventures, will be the Chair of the Kincell Board of Directors.

“Kincell represents a significant step forward in bridging the gap between laboratory research and clinical development of cell therapies. By addressing the manufacturing challenges faced by early-stage innovators, Kincell is playing a vital role in accelerating the progress of cell therapy innovation. We are excited to support their mission to make cell therapy manufacturing more accessible and streamlined, ultimately bringing life-changing treatments to patients in need.”

Bruce Thompson, the CEO of Kincell, will also serve on the Board of Directors.

“Kincell is at the forefront of innovative cell therapy manufacturing, and I am honoured to lead this exceptional team. Our mission is to enable early-stage biotech companies to bring their life-changing therapies to patients by providing accessible and high-quality manufacturing services,” said Thompson. “With our technology-forward approach and focus on immune cell therapies, we are poised to accelerate the advancement of cell therapies from bench to bedside. I am excited about the potential impact we can make in the field and look forward to collaborating with our partners to drive innovation and improve patients' lives.”